Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.

doi:10.1038/ncomms10767

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.

Nature communications - 24 Feb 2016

Merlevede Jane, Droin Nathalie, Qin Tingting, Meldi Kristen, Yoshida Kenichi, Morabito Margot, Chautard Emilie, Auboeuf Didier, Fenaux Pierre, Braun Thorsten, Itzykson Raphael, de Botton Stéphane, Quesnel Bruno, Commes Thérèse, Jourdan Eric, Vainchenker William, Bernard Olivier, Pata-Merci Noemie, Solier Stéphanie, Gayevskiy Velimir, Dinger Marcel E, Cowley Mark J, Selimoglu-Buet Dorothée, Meyer Vincent, Artiguenave François, Deleuze Jean-François, Preudhomme Claude, Stratton Michael R, Alexandrov Ludmil B, Padron Eric, Ogawa Seishi, Koscielny Serge, Figueroa Maria, Solary Eric

Abstract excerpt

The cytidine analogues azacytidine and 5-aza-2'-deoxycytidine (decitabine) are commonly used to treat myelodysplastic syndromes, with or without a myeloproliferative component. It remains unclear whether the response to these hypomethylating agents results from a cytotoxic or an epigenetic effect. In this study, we address this question in chronic myelomonocytic leukaemia. We describe a comprehensive analysis of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azacitidine

Share to Cell Survival

Share to Decitabine

Share to Epigenesis, Genetic

Share to HEK293 Cells

Share to Leukemia, Myelomonocytic, Chronic

Share to Sequence Analysis, RNA

Source

Open in PubMed Open full text

Identifiers

PMID: 26908133
DOI: 10.1038/ncomms10767
PMCID: PMC4770084

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.PMID 26908133Read ↗

Single cell genotyping of matched bone marrow and peripheral blood cells in treatment naive and AZA-treated MDS and CMMLSemantic proximity Read ↗

Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.Semantic proximity Read ↗

Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapySemantic proximity Read ↗

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.Semantic proximity Read ↗

DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective studySemantic proximity Read ↗

Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective.Semantic proximity Read ↗

Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy.Semantic proximity Read ↗

Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemiaSemantic proximity Read ↗

5-Azacytidine and decitabine induce C > G transversions in both murine and human cells.Semantic proximity Read ↗

Chronic myelomonocytic leukemia without increased classical monocyte subsets exhibits a distinct genetic profile, including frequent CBL mutations.Semantic proximity Read ↗

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemiaSemantic proximity Read ↗

Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.